---
title: "New Risk Nomograms for Prostate Cancer by PROMISE and PPP3"
id: "news-news-lancet-oncology-e34641ecfb72b33020931970"
canonical_url: "https://medichelpline.com/news/news-news-lancet-oncology-e34641ecfb72b33020931970"
content_type: "medical_news_article"
category: "Oncology"
source_name: "The Lancet Oncology"
source_url: "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00016-1/fulltext?rss=yes"
published_at: "2026-03-09T23:30:01.000Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# New Risk Nomograms for Prostate Cancer by PROMISE and PPP3
## Metadata & Source Attribution
- **Canonical URL:** https://medichelpline.com/news/news-news-lancet-oncology-e34641ecfb72b33020931970
- **Category:** [Oncology](https://medichelpline.com/news/oncology.md)
- **Reporting Source:** The Lancet Oncology
- **Original Source URL:** [Read Original Article](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00016-1/fulltext?rss=yes)
- **Published At:** 2026-03-09T23:30:01.000Z
## Executive Summary & Key Highlights
Recent research introduces risk nomograms to predict overall survival in prostate cancer over three, five, and seven years, utilizing PROMISE and PPP3 assessments.
## In-Depth Reporting & Editorial Analysis
Recent findings have unveiled new risk nomograms created by PROMISE, enabling healthcare professionals to predict overall survival rates in prostate cancer patients at three, five, and seven years. These assessments, known as PROMISE and PPP3, are designed for global use and are freely accessible online. This initiative aims to enhance prognostic capabilities in the management of prostate cancer, allowing better-informed decisions in patient care.
## Navigation
- [← Back to Oncology News](https://medichelpline.com/news/oncology.md)
- [← All Medical News Categories](https://medichelpline.com/news.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.